Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias^[1].

Naloxone (2.0 mg/kg with constant infusion of 1.7 mg/kg/h) causes a significant improvement in neurobehavioral outcome which persists up to 4 weeks postinjury in rat. Naloxone treatment causes a modest and nonsignificant increase in mean arterial blood pressure (MAP)^[1]. Naloxone (0.4 mg/kg) causes memory facilitation and antagonizes the amnestic effect of ACTH and epinephrine in rat^[2]. Naloxone treatment diminishes the strength of the initial tetanus in a dose-related manner in cats. Naloxone (5 or 10 mg/kg, i.v.) causes subsequent doses of morphine to produce less PTP depression but has no effect on maximal twitch depression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

363.84

C₁₉H₂₂ClNO₄

357-08-4

Solid

White to off-white

OC1=C(O2)C([C@]([C@]2(20)C(CC3)=O)(CCN4CC=C)[C@]3(O)[C@H]4C5)=C5C=C1.Cl

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. McIntosh TK, et al. Beneficial effect of the nonselective opiate antagonist naloxone hydrochloride and the thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following experimental brain injury in the rat. J Neurotrau  [Content Brief]

  [2]. Sun L, et al. Endocannabinoid activation of CB1 receptors contributes to long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation. Eur J Pain. 2017 May;21(5):804-814.  [Content Brief]

  [3]. Izquierdo I, et al. Effect of ACTH, epinephrine, beta-endorphin, naloxone, and of the combination of naloxone or beta-endorphinwith ACTH or epinephrine on memory consolidation. Psychoneuroendocrinology. 1983;8(1):81-7.  [Content Brief]

  [4]. Soteropoulos GC, et al. Neuromuscular effects of morphine and naloxone. J Pharmacol Exp Ther. 1973 Jan;184(1):136-42.  [Content Brief]